• Publications
  • Influence
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
TLDR
Recommendations: ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes, and Caution should be exercised when using ESAs with chemotherapeutic agents in diseases associated with increased risk of thromboembolic complications. Expand
Polycythemia vera: myths, mechanisms, and management.
Polycythemia vera is a clonal disorder arising in a multipotent hematopoietic progenitor cell that causes the accumulation of morphologically normal red cells, white cells, platelets, and theirExpand
Hematophagic Histiocytosis: A REPORT OF 23 NEW PATIENTS AND A REVIEW OF THE LITERATURE
TLDR
The principal features of this syndrome that distinguish it from malignant histiocytosis are the cytologic maturity and degree of hematophagic activity of the histiocytes as well as its more favorable prognosis. Expand
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders.
Human induced pluripotent stem (iPS) cells derived from somatic cells hold promise to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. We andExpand
Decreased erythropoietin response in patients with the anemia of cancer.
TLDR
It is concluded that erythropoietin levels are inappropriately low in anemia associated with cancer, and that eriespheric deficiency may contribute to the development of this form of anemia. Expand
Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
TLDR
Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of MpI or the lack of its expression, and appears to distinguish polycythemia vera from other-forms of erythrocytosis. Expand
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.
In its August 15, 2007, issue, Blood published a proposal for revision of the World Health Organization (WHO) diagnostic criteria for the chronic myeloproliferative disorders (MPDs) polycythemia veraExpand
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
TLDR
Recommendations: ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes, and Caution should be exercised when using ESAs with chemotherapeutic agents in diseases associated with increased risk of thromboembolic complications. Expand
Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis.
TLDR
K39N represents an identified functional Mpl polymorphism and is associated with altered protein expression of Mpl and a clinical phenotype of thrombocytosis and had a significantly higher platelet count than controls without the polymorphism. Expand
Chronic myeloproliferative disorders.
TLDR
It appears that overexpression of granulocyte PRV-1 in the presence of an elevated red cell mass supports a diagnosis of PV, and the therapeutic trade-off between reducing thrombotic events and increasing the risk of leukemia with the use of cytoreductive drugs should be approached by patient risk stratification. Expand
...
1
2
3
4
5
...